Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.
Identifieur interne : 000930 ( Main/Exploration ); précédent : 000929; suivant : 000931Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.
Auteurs : Amy N. Luckenbaugh [États-Unis] ; Gregory B. Auffenberg [États-Unis] ; Scott R. Hawken [États-Unis] ; Apoorv Dhir [États-Unis] ; Susan Linsell [États-Unis] ; Sanjeev Kaul [États-Unis] ; David C. Miller [États-Unis]Source :
- The Journal of urology [ 1527-3792 ] ; 2017.
Descripteurs français
- KwdFr :
- Adhésion aux directives (MeSH), Antigène spécifique de la prostate (sang), Biopsie (MeSH), Humains (MeSH), Michigan (MeSH), Mâle (MeSH), Observation (surveillance clinique) (MeSH), Sujet âgé (MeSH), Surveillance de la population (MeSH), Sélection de patients (MeSH), Tumeurs de la prostate (diagnostic), Tumeurs de la prostate (sang), Types de pratiques des médecins (MeSH), Urologie (MeSH).
- MESH :
- diagnostic : Tumeurs de la prostate.
- sang : Antigène spécifique de la prostate, Tumeurs de la prostate.
- Adhésion aux directives, Biopsie, Humains, Michigan, Mâle, Observation (surveillance clinique), Sujet âgé, Surveillance de la population, Sélection de patients, Types de pratiques des médecins, Urologie.
English descriptors
- KwdEn :
- Aged (MeSH), Biopsy (MeSH), Guideline Adherence (MeSH), Humans (MeSH), Male (MeSH), Michigan (MeSH), Patient Selection (MeSH), Population Surveillance (MeSH), Practice Patterns, Physicians' (MeSH), Prostate-Specific Antigen (blood), Prostatic Neoplasms (blood), Prostatic Neoplasms (diagnosis), Urology (MeSH), Watchful Waiting (MeSH).
- MESH :
- chemical , blood : Prostate-Specific Antigen.
- geographic : Michigan.
- blood : Prostatic Neoplasms.
- diagnosis : Prostatic Neoplasms.
- Aged, Biopsy, Guideline Adherence, Humans, Male, Patient Selection, Population Surveillance, Practice Patterns, Physicians', Urology, Watchful Waiting.
Abstract
PURPOSE
We examined the frequency of followup prostate specific antigen testing and prostate biopsy among men treated with active surveillance in the academic and community urology practices comprising MUSIC (Michigan Urological Surgery Improvement Collaborative).
MATERIALS AND METHODS
MUSIC is a consortium of 42 practices that maintains a prospective clinical registry with validated clinical data on all patients diagnosed with prostate cancer at participating sites. We identified all patients in MUSIC practices who entered active surveillance and had at least 2 years of continuous followup. After determining the frequency of repeat prostate specific antigen testing and prostate biopsy, we calculated rates of concordance with NCCN Guidelines® recommendations (ie at least 3 prostate specific antigen tests and 1 surveillance biopsy) collaborative-wide and across individual practices.
RESULTS
We identified 513 patients who entered active surveillance from January 2012 through September 2013 and had at least 2 years of followup. Among the 431 men (84%) who remained on active surveillance for 2 years 132 (30.6%) underwent followup surveillance testing at a frequency that was concordant with NCCN® (National Comprehensive Cancer Network®) recommendations. At the practice level, the median rate of guideline concordant followup was 26.5% (range 10% to 67.5%, p <0.001). Among patients with discordant followup, the absence of followup biopsy was common and not significantly different across practices (median rate 82.0%, p = 0.35).
CONCLUSIONS
Among diverse community and academic practices in Michigan, there is wide variation in the proportion of men on active surveillance who meet guideline recommendations for followup prostate specific antigen testing and repeat biopsy. These data highlight the need for standardized active surveillance pathways that emphasize the role of repeat surveillance biopsies.
DOI: 10.1016/j.juro.2016.09.071
PubMed: 27663459
PubMed Central: PMC5315618
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.</title><author><name sortKey="Luckenbaugh, Amy N" sort="Luckenbaugh, Amy N" uniqKey="Luckenbaugh A" first="Amy N" last="Luckenbaugh">Amy N. Luckenbaugh</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author><author><name sortKey="Auffenberg, Gregory B" sort="Auffenberg, Gregory B" uniqKey="Auffenberg G" first="Gregory B" last="Auffenberg">Gregory B. Auffenberg</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author><author><name sortKey="Hawken, Scott R" sort="Hawken, Scott R" uniqKey="Hawken S" first="Scott R" last="Hawken">Scott R. Hawken</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author><author><name sortKey="Dhir, Apoorv" sort="Dhir, Apoorv" uniqKey="Dhir A" first="Apoorv" last="Dhir">Apoorv Dhir</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author><author><name sortKey="Linsell, Susan" sort="Linsell, Susan" uniqKey="Linsell S" first="Susan" last="Linsell">Susan Linsell</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author><author><name sortKey="Kaul, Sanjeev" sort="Kaul, Sanjeev" uniqKey="Kaul S" first="Sanjeev" last="Kaul">Sanjeev Kaul</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author><author><name sortKey="Miller, David C" sort="Miller, David C" uniqKey="Miller D" first="David C" last="Miller">David C. Miller</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan. Electronic address: dcmiller@med.umich.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27663459</idno><idno type="pmid">27663459</idno><idno type="doi">10.1016/j.juro.2016.09.071</idno><idno type="pmc">PMC5315618</idno><idno type="wicri:Area/Main/Corpus">000B10</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B10</idno><idno type="wicri:Area/Main/Curation">000B10</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000B10</idno><idno type="wicri:Area/Main/Exploration">000B10</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.</title><author><name sortKey="Luckenbaugh, Amy N" sort="Luckenbaugh, Amy N" uniqKey="Luckenbaugh A" first="Amy N" last="Luckenbaugh">Amy N. Luckenbaugh</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author><author><name sortKey="Auffenberg, Gregory B" sort="Auffenberg, Gregory B" uniqKey="Auffenberg G" first="Gregory B" last="Auffenberg">Gregory B. Auffenberg</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author><author><name sortKey="Hawken, Scott R" sort="Hawken, Scott R" uniqKey="Hawken S" first="Scott R" last="Hawken">Scott R. Hawken</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author><author><name sortKey="Dhir, Apoorv" sort="Dhir, Apoorv" uniqKey="Dhir A" first="Apoorv" last="Dhir">Apoorv Dhir</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author><author><name sortKey="Linsell, Susan" sort="Linsell, Susan" uniqKey="Linsell S" first="Susan" last="Linsell">Susan Linsell</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author><author><name sortKey="Kaul, Sanjeev" sort="Kaul, Sanjeev" uniqKey="Kaul S" first="Sanjeev" last="Kaul">Sanjeev Kaul</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author><author><name sortKey="Miller, David C" sort="Miller, David C" uniqKey="Miller D" first="David C" last="Miller">David C. Miller</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan. Electronic address: dcmiller@med.umich.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak</wicri:cityArea></affiliation></author></analytic><series><title level="j">The Journal of urology</title><idno type="eISSN">1527-3792</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Biopsy (MeSH)</term><term>Guideline Adherence (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Michigan (MeSH)</term><term>Patient Selection (MeSH)</term><term>Population Surveillance (MeSH)</term><term>Practice Patterns, Physicians' (MeSH)</term><term>Prostate-Specific Antigen (blood)</term><term>Prostatic Neoplasms (blood)</term><term>Prostatic Neoplasms (diagnosis)</term><term>Urology (MeSH)</term><term>Watchful Waiting (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adhésion aux directives (MeSH)</term><term>Antigène spécifique de la prostate (sang)</term><term>Biopsie (MeSH)</term><term>Humains (MeSH)</term><term>Michigan (MeSH)</term><term>Mâle (MeSH)</term><term>Observation (surveillance clinique) (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Surveillance de la population (MeSH)</term><term>Sélection de patients (MeSH)</term><term>Tumeurs de la prostate (diagnostic)</term><term>Tumeurs de la prostate (sang)</term><term>Types de pratiques des médecins (MeSH)</term><term>Urologie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Prostate-Specific Antigen</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Michigan</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Antigène spécifique de la prostate</term><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Biopsy</term><term>Guideline Adherence</term><term>Humans</term><term>Male</term><term>Patient Selection</term><term>Population Surveillance</term><term>Practice Patterns, Physicians'</term><term>Urology</term><term>Watchful Waiting</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adhésion aux directives</term><term>Biopsie</term><term>Humains</term><term>Michigan</term><term>Mâle</term><term>Observation (surveillance clinique)</term><term>Sujet âgé</term><term>Surveillance de la population</term><term>Sélection de patients</term><term>Types de pratiques des médecins</term><term>Urologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>PURPOSE</b></p><p>We examined the frequency of followup prostate specific antigen testing and prostate biopsy among men treated with active surveillance in the academic and community urology practices comprising MUSIC (Michigan Urological Surgery Improvement Collaborative).</p></div><div type="abstract" xml:lang="en"><p><b>MATERIALS AND METHODS</b></p><p>MUSIC is a consortium of 42 practices that maintains a prospective clinical registry with validated clinical data on all patients diagnosed with prostate cancer at participating sites. We identified all patients in MUSIC practices who entered active surveillance and had at least 2 years of continuous followup. After determining the frequency of repeat prostate specific antigen testing and prostate biopsy, we calculated rates of concordance with NCCN Guidelines® recommendations (ie at least 3 prostate specific antigen tests and 1 surveillance biopsy) collaborative-wide and across individual practices.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>We identified 513 patients who entered active surveillance from January 2012 through September 2013 and had at least 2 years of followup. Among the 431 men (84%) who remained on active surveillance for 2 years 132 (30.6%) underwent followup surveillance testing at a frequency that was concordant with NCCN® (National Comprehensive Cancer Network®) recommendations. At the practice level, the median rate of guideline concordant followup was 26.5% (range 10% to 67.5%, p <0.001). Among patients with discordant followup, the absence of followup biopsy was common and not significantly different across practices (median rate 82.0%, p = 0.35).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Among diverse community and academic practices in Michigan, there is wide variation in the proportion of men on active surveillance who meet guideline recommendations for followup prostate specific antigen testing and repeat biopsy. These data highlight the need for standardized active surveillance pathways that emphasize the role of repeat surveillance biopsies.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27663459</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3792</ISSN><JournalIssue CitedMedium="Internet"><Volume>197</Volume><Issue>3 Pt 1</Issue><PubDate><Year>2017</Year><Month>03</Month></PubDate></JournalIssue><Title>The Journal of urology</Title><ISOAbbreviation>J Urol</ISOAbbreviation></Journal><ArticleTitle>Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.</ArticleTitle><Pagination><MedlinePgn>621-626</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0022-5347(16)31304-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2016.09.071</ELocationID><Abstract><AbstractText Label="PURPOSE">We examined the frequency of followup prostate specific antigen testing and prostate biopsy among men treated with active surveillance in the academic and community urology practices comprising MUSIC (Michigan Urological Surgery Improvement Collaborative).</AbstractText><AbstractText Label="MATERIALS AND METHODS">MUSIC is a consortium of 42 practices that maintains a prospective clinical registry with validated clinical data on all patients diagnosed with prostate cancer at participating sites. We identified all patients in MUSIC practices who entered active surveillance and had at least 2 years of continuous followup. After determining the frequency of repeat prostate specific antigen testing and prostate biopsy, we calculated rates of concordance with NCCN Guidelines® recommendations (ie at least 3 prostate specific antigen tests and 1 surveillance biopsy) collaborative-wide and across individual practices.</AbstractText><AbstractText Label="RESULTS">We identified 513 patients who entered active surveillance from January 2012 through September 2013 and had at least 2 years of followup. Among the 431 men (84%) who remained on active surveillance for 2 years 132 (30.6%) underwent followup surveillance testing at a frequency that was concordant with NCCN® (National Comprehensive Cancer Network®) recommendations. At the practice level, the median rate of guideline concordant followup was 26.5% (range 10% to 67.5%, p <0.001). Among patients with discordant followup, the absence of followup biopsy was common and not significantly different across practices (median rate 82.0%, p = 0.35).</AbstractText><AbstractText Label="CONCLUSIONS">Among diverse community and academic practices in Michigan, there is wide variation in the proportion of men on active surveillance who meet guideline recommendations for followup prostate specific antigen testing and repeat biopsy. These data highlight the need for standardized active surveillance pathways that emphasize the role of repeat surveillance biopsies.</AbstractText><CopyrightInformation>Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luckenbaugh</LastName><ForeName>Amy N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auffenberg</LastName><ForeName>Gregory B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawken</LastName><ForeName>Scott R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhir</LastName><ForeName>Apoorv</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linsell</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaul</LastName><ForeName>Sanjeev</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan. Electronic address: dcmiller@med.umich.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Michigan Urological Surgery Improvement Collaborative</CollectiveName><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan; Comprehensive Urology, William Beaumont Hospital (SK), Royal Oak, Michigan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 CA180984</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Urol</MedlineTA><NlmUniqueID>0376374</NlmUniqueID><ISSNLinking>0022-5347</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.77</RegistryNumber><NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2017 Mar;197(3 Pt 1):625-626</RefSource><PMID Version="1">27908692</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019983" MajorTopicYN="Y">Guideline Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008824" MajorTopicYN="N" Type="Geographic">Michigan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="Y">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="Y">Population Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="Y">Practice Patterns, Physicians'</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014572" MajorTopicYN="Y">Urology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057832" MajorTopicYN="N">Watchful Waiting</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">biopsy</Keyword><Keyword MajorTopicYN="Y">prostate-specific antigen</Keyword><Keyword MajorTopicYN="Y">prostatic neoplasms</Keyword><Keyword MajorTopicYN="Y">quality improvement</Keyword><Keyword MajorTopicYN="Y">watchful waiting</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27663459</ArticleId><ArticleId IdType="pii">S0022-5347(16)31304-0</ArticleId><ArticleId IdType="doi">10.1016/j.juro.2016.09.071</ArticleId><ArticleId IdType="pmc">PMC5315618</ArticleId><ArticleId IdType="mid">NIHMS817996</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Natl Compr Canc Netw. 2015 Dec;13(12 ):1534-61</Citation><ArticleIdList><ArticleId IdType="pubmed">26656522</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2011 Jun 1;29(16):2185-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21464416</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Compr Canc Netw. 2010 Feb;8(2):162-200</Citation><ArticleIdList><ArticleId IdType="pubmed">20141676</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2015 Nov;68(5):814-21</Citation><ArticleIdList><ArticleId IdType="pubmed">26138043</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2012 Dec;62(6):976-83</Citation><ArticleIdList><ArticleId IdType="pubmed">22698574</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2013 Nov;190(5):1742-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23727309</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2007 Jun;177(6):2106-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17509297</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2015 Aug;194(2):403-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25896556</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Manag Care. 2014 Nov;20(11 Spec No. 17):SP502-10</Citation><ArticleIdList><ArticleId IdType="pubmed">25811824</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Compr Canc Netw. 2014 May;12(5):686-718</Citation><ArticleIdList><ArticleId IdType="pubmed">24812137</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2016 Sep;196(3):721-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26946161</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Urol Rep. 2010 May;11(3):165-71</Citation><ArticleIdList><ArticleId IdType="pubmed">20425623</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 2011 May 15;117(10):2058-66</Citation><ArticleIdList><ArticleId IdType="pubmed">21523717</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2014 Jul;192(1):75-80</Citation><ArticleIdList><ArticleId IdType="pubmed">24518783</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 2008 Jun 15;112(12):2664-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18433013</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2015 Nov;86(5):901-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26358397</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2013 Apr;63(4):597-603</Citation><ArticleIdList><ArticleId IdType="pubmed">23159452</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2015 Jul 7;314(1):80-2</Citation><ArticleIdList><ArticleId IdType="pubmed">26151271</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Compr Canc Netw. 2016 Jan;14 (1):19-30</Citation><ArticleIdList><ArticleId IdType="pubmed">26733552</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2015 Mar;193(3):807-11</Citation><ArticleIdList><ArticleId IdType="pubmed">25261803</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2015 Jan;67(1):44-50</Citation><ArticleIdList><ArticleId IdType="pubmed">25159890</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Cancer Inst. 2006 Aug 16;98(16):1134-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16912266</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Michigan</li></region></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Luckenbaugh, Amy N" sort="Luckenbaugh, Amy N" uniqKey="Luckenbaugh A" first="Amy N" last="Luckenbaugh">Amy N. Luckenbaugh</name></region><name sortKey="Auffenberg, Gregory B" sort="Auffenberg, Gregory B" uniqKey="Auffenberg G" first="Gregory B" last="Auffenberg">Gregory B. Auffenberg</name><name sortKey="Dhir, Apoorv" sort="Dhir, Apoorv" uniqKey="Dhir A" first="Apoorv" last="Dhir">Apoorv Dhir</name><name sortKey="Hawken, Scott R" sort="Hawken, Scott R" uniqKey="Hawken S" first="Scott R" last="Hawken">Scott R. Hawken</name><name sortKey="Kaul, Sanjeev" sort="Kaul, Sanjeev" uniqKey="Kaul S" first="Sanjeev" last="Kaul">Sanjeev Kaul</name><name sortKey="Linsell, Susan" sort="Linsell, Susan" uniqKey="Linsell S" first="Susan" last="Linsell">Susan Linsell</name><name sortKey="Miller, David C" sort="Miller, David C" uniqKey="Miller D" first="David C" last="Miller">David C. Miller</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SanteMusiqueV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000930 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000930 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SanteMusiqueV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27663459
|texte= Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27663459" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SanteMusiqueV1
| This area was generated with Dilib version V0.6.38. |  |